metformin has been researched along with Leiomyoma in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uterine leiomyomas are the most common gynecological benign tumors and greatly affect reproductive health and wellbeing." | 5.39 | The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. ( Kitamura, M; Kondo, A; Li, B; Takeda, T; Tsuiji, K; Wong, TF; Yaegashi, N, 2013) |
| "The aim of this study was to elucidate whether metformin can regulate the expression of vascular endothelial growth factor (VEGF) in rat-derived uterine leiomyoma cells (ELT-3 cells)." | 3.81 | The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. ( Li, B; Tadakawa, M; Takeda, T; Tsuiji, K; Yaegashi, N, 2015) |
| "Uterine leiomyomas are the most common gynecological benign tumors and greatly affect reproductive health and wellbeing." | 1.39 | The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. ( Kitamura, M; Kondo, A; Li, B; Takeda, T; Tsuiji, K; Wong, TF; Yaegashi, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadakawa, M | 1 |
| Takeda, T | 2 |
| Li, B | 2 |
| Tsuiji, K | 2 |
| Yaegashi, N | 2 |
| Zhang, L | 1 |
| Liao, Q | 1 |
| Kondo, A | 1 |
| Kitamura, M | 1 |
| Wong, TF | 1 |
3 other studies available for metformin and Leiomyoma
| Article | Year |
|---|---|
The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; | 2015 |
Effects of testosterone and metformin on glucose metabolism in endometrium.
Topics: Adult; Cells, Cultured; Endometriosis; Endometrium; Epithelial Cells; Female; Follicular Phase; Gene | 2010 |
The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Hum | 2013 |